BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Business > article

Samsung Biologics scores victory in patent suit against Lonza of Switzerland

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : October 14, 2019, 15:01 | Updated : October 14, 2019, 15:01
  • 트위터
  • 페이스북
  • 웨이보

[Courtesy of Samsung BioLogics]

SEOUL -- Samsung BioLogics, a leading bio company in South Korea, has scored a meaningful legal victory against Lonza, a Swiss chemicals and biotechnology company, to nullify patents involving cell line development technology

With the Korean Intellectual Property Tribunal's ruling, Samsung BioLogics said it can expand its contract development organization (CDO) business portfolio. CDO is a business that develops cell lines and production processes for the mass production of antibody-drug candidate substances developed at the laboratory level.

The cell line refers to cells that multiply massively to make desired antibody drugs. The patent is for some proteins that help cell line proliferation. The tribunal has ruled that Lonza's patent is not new as it is identical to the previously known technology and it can be easily invented by an ordinary engineer. Lonza can appeal the decision.

Samsung BioLogics filed for patent nullification in July 2017 on DNA vectors, which transfer genes for the production of antibodies into cell lines. In molecular cloning, a vector is a DNA molecule used as a vehicle to artificially carry foreign genetic material into another cell, where it can be replicated or expressed.

Samsung BioLogics has sought patent nullification, saying Lonza's patent was acting as an unfair entry barrier as it expanded its biomedicine business from contract manufacturing organization (CMO) to CDO. Samsung Biologics has signed 34 CDO contracts with clients.

CMO serves other companies in the pharmaceutical industry to provide comprehensive services from development through manufacturing. Lonza is a leading contract development and manufacturing organization (CDMO) that concurrently conducts CDO and CMO.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Samsung Biologics secures deal to mass-produce Lillys antibody treatment .
    Samsung Biologics secures deal to mass-produce Lilly's antib…
  • .​Samsung Biologics forges strategic partnership with Chinas GeneQuantum.
    ​Samsung Biologics forges strategic partnership with China's…
  • .Samsung BioLogics wins $314 mln CMO deal from unnamed European client.
    Samsung BioLogics wins $314 mln CMO deal from unnamed Europe…
  • .Samsung Bioepis allowed to go ahead with clinical trial in China for biosimilar candidate.
    Samsung Bioepis allowed to go ahead with clinical trial in C…
  • .Samsung Bioepis cancer-treating biosimilar Ontruzant is available in U.S. .
    Samsung Bioepis' cancer-treating biosimilar Ontruzant is ava…

Real Time Photo News

  • .Singer HyunA to end 14-month hiatus with mini-album Im Not Cool.

    Singer HyunA to end 14-month hiatus with mini-album 'I'm Not Cool'

  • .NCSofts global K-pop fan community platform to service original content including songs.

    NCSoft's global K-pop fan community platform to service original content including songs

  • .Singer IU drops teaser image for upcoming full album.

    Singer IU drops teaser image for upcoming full album

  • .Cube Entertainment partners with web comics company to create online video content.

    Cube Entertainment partners with web comics company to create online video content

  • .Sci-fi film starring Song Joong-ki to be reelased on Netflix in February.

    Sci-fi film starring Song Joong-ki to be reelased on Netflix in February

Latest News

more+

  • LA-bound Maersk containership loses some 750 containers overboard in Pacific
  • SK Bioscience selected to manage COVID-19 vaccine distribution in S. Korea
  • S. Korea finalizes official process of imposing 513% tariff on imported rice
  • Verizon becomes first to deploy Samsung's fully virtualized 5G solutions
  • Singer HyunA to end 14-month hiatus with mini-album 'I'm Not Cool'
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view